|
1
|
Yan Y, Liang H, Li T, Li M, Li R, Qin X
and Li S: The MMP-1, MMP-2, and MMP-9 gene polymorphisms and
susceptibility to bladder cancer: A meta-analysis. Tumour Biol.
35:3047–3052. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Cancer Genome Atlas Research Network.
Comprehensive molecular characterization of urothelial bladder
carcinoma. Nature. 507:315–322. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Kanayama H: Matrix metalloproteinases and
bladder cancer. J Med Invest. 48:31–43. 2001.PubMed/NCBI
|
|
4
|
Vargová V, Pytliak M and Mechírová V:
Matrix metalloproteinases. EXS. 103:1–33. 2012.PubMed/NCBI
|
|
5
|
Lai WC, Zhou M, Shankavaram U, Peng G and
Wahl LM: Differential regulation of lipopolysaccharide-induced
monocyte matrix metalloproteinase (MMP)-1 and MMP-9 by p38 and
extracellular signal-regulated kinase 1/2 mitogen-activated protein
kinases. J Immunol. 170:6244–6249. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Westermarck J and Kähäri VM: Regulation of
matrix metalloproteinase expression in tumor invasion. FASEB J.
13:781–792. 1999.PubMed/NCBI
|
|
7
|
Chung TW, Lee YC and Kim CH: Hepatitis B
viral HBx induces matrix metalloproteinase-9 gene expression
through activation of ERK and PI-3K/AKT pathways: Involvement of
invasive potential. FASEB J. 18:1123–1125. 2004.PubMed/NCBI
|
|
8
|
Cheng JC, Chou CH, Kuo ML and Hsieh CY:
Radiation-enhanced hepatocellular carcinoma cell invasion with
MMP-9 expression through PI3K/Akt/NF-kappaB signal transduction
pathway. Oncogene. 25:7009–7018. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Adya R, Tan BK, Punn A, Chen J and Randeva
HS: Visfatin induces human endothelial VEGF and MMP-2/9 production
via MAPK and PI3K/Akt signalling pathways: Novel insights into
visfatin-induced angiogenesis. Cardiovasc Res. 78:356–365. 2008.
View Article : Google Scholar
|
|
10
|
Sen M, Reifert J, Lauterbach K, Wolf V,
Rubin JS, Corr M and Carson DA: Regulation of fibronectin and
metalloproteinase expression by Wnt signaling in rheumatoid
arthritis synoviocytes. Arthritis Rheum. 46:2867–2877. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Yang JM, Xu Z, Wu H, Zhu H, Wu X and Hait
WN: Overexpression of extracellular matrix metalloproteinase
inducer in multidrug resistant cancer cells. Mol Cancer Res.
1:420–427. 2003.PubMed/NCBI
|
|
12
|
Sethi T, Rintoul RC, Moore SM, MacKinnon
AC, Salter D, Choo C, Chilvers ER, Dransfield I, Donnelly SC,
Strieter R, et al: Extracellular matrix proteins protect small cell
lung cancer cells against apoptosis: A mechanism for small cell
lung cancer growth and drug resistance in vivo. Nat Med. 5:662–668.
1999. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Lee HJ, Song IC, Yun HJ, Jo DY and Kim S:
CXC chemokines and chemokine receptors in gastric cancer: From
basic findings towards therapeutic targeting. World J
Gastroenterol. 20:1681–1693. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Mukaida N and Baba T: Chemokines in tumor
development and progression. Exp Cell Res. 318:95–102. 2012.
View Article : Google Scholar
|
|
15
|
Gorbachev AV and Fairchild RL: Regulation
of chemokine expression in the tumor microenvironment. Crit Rev
Immunol. 34:103–120. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kawamura M, Toiyama Y, Tanaka K, Saigusa
S, Okugawa Y, Hiro J, Uchida K, Mohri Y, Inoue Y and Kusunoki M:
CXCL5, a promoter of cell proliferation, migration and invasion, is
a novel serum prognostic marker in patients with colorectal cancer.
Eur J Cancer. 48:2244–2251. 2012. View Article : Google Scholar
|
|
17
|
Zhou SL, Dai Z, Zhou ZJ, Chen Q, Wang Z,
Xiao YS, Hu ZQ, Huang XY, Yang GH, Shi YH, et al: CXCL5 contributes
to tumor metastasis and recurrence of intrahepatic
cholangiocarcinoma by recruiting infiltrative intratumoral
neutrophils. Carcinogenesis. 35:597–605. 2014. View Article : Google Scholar
|
|
18
|
Kuo PL, Chen YH, Chen TC, Shen KH and Hsu
YL: CXCL5/ENA78 increased cell migration and
epithelial-to-mesenchymal transition of hormone-independent
prostate cancer by early growth response-1/snail signaling pathway.
J Cell Physiol. 226:1224–1231. 2011. View Article : Google Scholar
|
|
19
|
Begley LA, Kasina S, Mehra R, Adsule S,
Admon AJ, Lonigro RJ, Chinnaiyan AM and Macoska JA: CXCL5 promotes
prostate cancer progression. Neoplasia. 10:244–254. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Park JY, Park KH, Bang S, Kim MH, Lee JE,
Gang J, Koh SS and Song SY: CXCL5 overexpression is associated with
late stage gastric cancer. J Cancer Res Clin Oncol. 133:835–840.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Miyazaki H, Patel V, Wang H, Edmunds RK,
Gutkind JS and Yeudall WA: Down-regulation of CXCL5 inhibits
squamous carcinogenesis. Cancer Res. 66:4279–4284. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zheng J, Zhu X and Zhang J: CXCL5
knockdown expression inhibits human bladder cancer T24 cells
proliferation and migration. Biochem Biophys Res Commun. 446:18–24.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Toker A and Marmiroli S: Signaling
specificity in the Akt pathway in biology and disease. Adv Biol
Regul. 55:28–38. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Yang Z, Li Z, Feng H, Bian X and Liu Y and
Liu Y: Enhanced growth inhibition by combined two pathway
inhibitors on K-ras mutated non-small cell lung cancer cells.
Zhonghua Zhong Liu Za Zhi. 36:645–650. 2014.(In Chinese).
|
|
25
|
Polivka J Jr and Janku F: Molecular
targets for cancer therapy in the PI3K/AKT/mTOR pathway. Pharmacol
Ther. 142:164–175. 2014. View Article : Google Scholar
|
|
26
|
Houédé N and Pourquier P: Targeting the
genetic alterations of the PI3K-AKT-mTOR pathway: Its potential use
in the treatment of bladder cancers. Pharmacol Ther. 145:1–18.
2015. View Article : Google Scholar
|
|
27
|
Martini M, De Santis MC, Braccini L,
Gulluni F and Hirsch E: PI3K/AKT signaling pathway and cancer: An
updated review. Ann Med. 46:372–383. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Heavey S, O’Byrne KJ and Gately K:
Strategies for co-targeting the PI3K/AKT/mTOR pathway in NSCLC.
Cancer Treat Rev. 40:445–456. 2014. View Article : Google Scholar
|
|
29
|
Saintigny P, Massarelli E, Lin S, Ahn YH,
Chen Y, Goswami S, Erez B, O’Reilly MS, Liu D, Lee JJ, et al: CXCR2
expression in tumor cells is a poor prognostic factor and promotes
invasion and metastasis in lung adenocarcinoma. Cancer Res.
73:571–582. 2013. View Article : Google Scholar :
|
|
30
|
Würth R, Bajetto A, Harrison JK, Barbieri
F and Florio T: CXCL12 modulation of CXCR4 and CXCR7 activity in
human glioblastoma stem-like cells and regulation of the tumor
microenvironment. Front Cell Neurosci. 8:1442014.PubMed/NCBI
|
